Champions Oncology, Inc.CSBR

Champions Oncology, Inc. is a contract research organisation that sells laboratory services to drug developers rather than a biotech with its own drug pipeline. Its core offerings are preclinical and clinical testing tools-early drug discovery workflows, clinical bioanalysis, histopathology and immunohistochemistry, Western blot analysis, and 4D quantitative proteomics-positioned as a one-stop shop for oncology-focused CRO services. The company markets speed, cost-effectiveness, and proprietary data assets such as its PDX bank and clinical treatment-response data, but the filings do not show a single FDA-approved product or therapy revenue stream deriving from its own R&D.

The latest SEC filings paint a picture of a service business that is operationally real but financially fragile. In the quarter ended 31 January 2026, Champions Oncology recorded $16.6 million of revenue from customer contracts, up from the prior comparable period, but posted a net loss of $279,000 and an operating loss of $276,000. Diluted earnings per share were minus two cents on a diluted share count of 13.9 million. Cash used in operating activities was $2.5 million, while the company spent $325,000 on property, plant, and equipment. Research and development expense was $2.3 million, underscoring that the company is still investing heavily in platform and service development rather than harvesting profit.

The balance sheet shows $28.4 million of assets against $24.1 million of liabilities, leaving shareholders with $4.3 million of equity and $7.1 million of cash and cash equivalents at period end. The company’s liquidity position is therefore constrained by the pace of cash burn, even if the cash balance is positive. There is no dividend, no buyback programme, and no declared guidance in the 10-Q; the board’s March 2026 8-K did authorise a $25 million ATM equity programme, which gives the company the option to tap the market but also raises dilution risk in a thinly traded micro-cap stock.

The company’s five service verticals are live on the website, each illustrated with stock images and claims of industry-leading expertise. Products include early drug discovery services, clinical bioanalytical services, preclinical histology and IHC, Western blot services, and 4D proteomics. The proteomics page highlights Champions’ proprietary Lumin software and the use of a PDX bank tied to more than 12,000 cancer patients, positioning the data asset as a differentiator. While these offerings are legitimate laboratory services, the filings do not quantify customer concentration, renewal rates, or margin expansion-details that would materially affect the investment case.

Champions Oncology trades on the OTCQB under the symbol CSBR. The absence of NYSE or Nasdaq listing and the modest trading volumes mean liquidity is thin, and price discovery is driven by sporadic news flow and periodic filings rather than a deep order book. For readers seeking chart context, TradingView route CSBR is available but should be interpreted with caution given the micro-cap liquidity profile.

The company has not provided segment-level disclosures in the 10-Q, so it is impossible to discern which service line is driving the $16.6 million of revenue or whether any single client represents a material portion of the top line. The lack of segment data and the absence of forward-looking guidance in the latest filings leave investors to infer performance rather than measure it. Until the company publishes a 10-K with audited annual figures, a detailed breakdown of customer concentration, and explicit guidance, the investment case will remain speculative.